Search research articles
Contact Us
Filters
Showing results (611-620 of 645) with videos related to
Page
of 65
Sort By:
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Kidney International
|
July 16, 2004
Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome
Rainer G Ruf, Michael Schultheiss, Anne Lichtenberger, et al.
Clinical Rheumatology
|
December 2, 2010
B cell depletion for autoimmune diseases in paediatric patients
Annette F Jansson, Claudia Sengler, Jasmin Kuemmerle-Deschner, et al.
Scientific Reports
|
September 18, 2020
A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease
Tatsuya Ikenoue, Francesco A Aprile, Pietro Sormanni, et al.
The Journal of Urology
|
December 28, 2020
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
The Journal of Urology
|
March 11, 2021
Reply by Authors
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
Urology
|
March 6, 2012
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109
Ryan K Berglund, Catherine M Tangen, Isaac J Powell, et al.
Science Translational Medicine
|
March 22, 2013
Terminally differentiated CD8⁺ T cells negatively affect bone regeneration in humans
Simon Reinke, Sven Geissler, William R Taylor, et al.
Prostate Cancer and Prostatic Diseases
|
August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Page
of 65
Search research articles
Search
Showing results (611-620 of 645) with videos related to
Sort By:
Page
of 65
Future Oncology (London, England)
|
December 12, 2024
Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
Future Oncology (London, England)
|
June 30, 2025
Enzalutamide treatment of patients with advanced prostate cancer across the disease spectrum: plain language review
Paul E Dato, Jose De La Cerda, Andrew J Armstrong, et al.
Kidney International
|
July 16, 2004
Prevalence of WT1 mutations in a large cohort of patients with steroid-resistant and steroid-sensitive nephrotic syndrome
Rainer G Ruf, Michael Schultheiss, Anne Lichtenberger, et al.
Clinical Rheumatology
|
December 2, 2010
B cell depletion for autoimmune diseases in paediatric patients
Annette F Jansson, Claudia Sengler, Jasmin Kuemmerle-Deschner, et al.
Scientific Reports
|
September 18, 2020
A rationally designed bicyclic peptide remodels Aβ42 aggregation in vitro and reduces its toxicity in a worm model of Alzheimer's disease
Tatsuya Ikenoue, Francesco A Aprile, Pietro Sormanni, et al.
The Journal of Urology
|
December 28, 2020
Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
The Journal of Urology
|
March 11, 2021
Reply by Authors
Andrew J Armstrong, Neal D Shore, Russell Z Szmulewitz, et al.
Urology
|
March 6, 2012
Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109
Ryan K Berglund, Catherine M Tangen, Isaac J Powell, et al.
Science Translational Medicine
|
March 22, 2013
Terminally differentiated CD8⁺ T cells negatively affect bone regeneration in humans
Simon Reinke, Sven Geissler, William R Taylor, et al.
Prostate Cancer and Prostatic Diseases
|
August 22, 2021
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, et al.
Page
of 65